File #: 24-5566    Version: 1 Name: EIDOS Research Study
Type: Grant Award Status: Approved
File created: 9/30/2024 In control: Board of Commissioners
On agenda: 10/24/2024 Final action: 10/24/2024
Title: PROPOSED GRANT AWARD Department: Cook County Health Grantee: Cook County Health Grantor: EIDOS Request: Authorization to setup new research award for EIDOS Purpose: The purpose of this research study is for a A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) Grant Amount: $560,443.00 Grant Period: 10/1/2024 - 11/30/2029 Fiscal Impact: $560,443.00 Accounts: N/A. Concurrences: The Budget Department has received all requisite documents and determined the fiscal impact on Cook County, if any Summary: This Extramural Commercial contract with Edios is a 5-year trial to is for a A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) look at. The Contract amount of $560,443 is the maximum that could be earned and depends on services rendered and numb...
Indexes: (Inactive) ERIK MIKAITIS, M.D., Interim Chief Executive Officer, Cook County Health and Hospitals Systems
Attachments: 1. Eidos_AG10501_US Schedule A_10May2024 CCH.6.3.2024 draft (002).pdf

title

PROPOSED GRANT AWARD

 

Department:  Cook County Health

 

Grantee:  Cook County Health 

 

Grantor:  EIDOS

 

Request: Authorization to setup new research award for EIDOS

 

Purpose:  The purpose of this research study is for a A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

 

Grant Amount:  $560,443.00 

 

Grant Period:  10/1/2024 - 11/30/2029

 

Fiscal Impact:  $560,443.00 

 

Accounts: N/A.

 

Concurrences:

The Budget Department has received all requisite documents and determined the fiscal impact on Cook County, if any

 

Summary:  This Extramural Commercial contract with Edios is a 5-year trial to is for a A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) look at. The Contract amount of $560,443 is the maximum that could be earned and depends on services rendered and number of subjects enrolled in the clinical trial. We will look to start spending in October of 2024 and approximately spend 5% of the contract amount in year1 with ramp up spend in years 2-4, and ramp down spend, once the contract is near completion.

end